Abstract 611
Case Summary
A 61-year-old man, presented with painless gross hematuria and palpable mass at suprapubic area. Computed tomography (CT) of abdomen showed enhancing mixed solid-cystic mass size 4 x 3.6 cm originating at the right anterior dome of bladder. He underwent exploratory laparotomy with partial cystectomy with urachal excision. Histopathology reported adenocarcinoma, margin is not free. Immunohistochemistry staining showed positive CK20, CDX2, focally positive CK7 and negative PSA. He was diagnosed with urachal carcinoma stage IIIA by Sheldon et al. classification. That time he did not received any adjuvant chemotherapy and radiotherapy. Five months later, he developed recurrent suprapubic area mass and painless gross hematuria. His physical examination of abdomen showed palpable lobulated fixed hard consistency mass at dome of bladder to lower midline of abdomen. CT of abdomen showed enhancing nodule at the left anterior-inferior aspect of the bladder, and hypodense lesion on midline surgical scar at lower abdomen. He was diagnosed with recurrent locally advanced urachal carcinoma stage IIIB. He was treated by pre-operative concurrent chemoradiotherapy(CCRT) with 5-Flurouracil(5FU) with 350 mg/m2day 1-5 and day 28-33. CT of the abdomen after completion of CCRT showed decreasing size of nodular thickening at the left anterolateral aspect of bladder from 2.8 cm to 1.3 cm (17.8%), no substantial change in size of enhancing soft tissue mass on midline surgical scar. Then he was treated with exploratory laparotomy with tumor removal and partial cystectomy. Histopathology showed adenocarcinoma with mucin production, margin is not free. Multidisciplinary team decided to treat with adjuvant chemotherapy with 5FU-based regimen.
Urachal cancer is a very rare cancer carrying poor prognosis in genitourinary tract cancers. It may present with different clinical manifestations, including an abdominal mass, hematuria and pain. Surgical resection is a main strategy for treatment. There has been no standard regimen for neoadjuvant or adjuvant chemotherapy and radiotherapy. This case showed a favorable response from induction CCRT with 5-FU following by surgery in locally advance urachal adenocarcinoma.
Editorial acknowledgement
Clinical trial identification
Resources from the same session
750 - HER2 positive rates in Invasive Lobular Breast Carcinoma : A study amongst 1,095 consecutive Asian patients
Presenter: Ga Jing Kee
Session: Poster display - Cocktail
Resources:
Abstract
1417 - CanAssist-breast -an immunohistochemistry based test for risk of recurrence prediction for early stage breast cancer patients: a cost-effective and accurate solution for Asia
Presenter: Manjiri Bakre
Session: Poster display - Cocktail
Resources:
Abstract
1468 - Topical silymarin administration for prevention of radiodermatitis in breast cancer patients: a randomized, double-blind, placebo-controlled clinical trial
Presenter: Sepideh Elyasi
Session: Poster display - Cocktail
Resources:
Abstract
873 - Comparison of interstitial brachytherapy with volumetric modulated arc therapy for tumour bed boost following breast conservative surgery
Presenter: Kannan Periasamy
Session: Poster display - Cocktail
Resources:
Abstract
1140 - Triple Negative Breast Cancer and Platinum-based Systemic Treatment: Meta-analysis and Systematic Review
Presenter: Jessa Gilda Pandy
Session: Poster display - Cocktail
Resources:
Abstract
168 - Longitudinal study on incidences of obesity and weight changes in Chinese patients with early-stage breast cancer
Presenter: Winnie Yeo
Session: Poster display - Cocktail
Resources:
Abstract
311 - Effect of combined CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome in breast cancer indicates endogenous and exogenous interplay
Presenter: Hanjing Xie
Session: Poster display - Cocktail
Resources:
Abstract
669 - A novel nipple aleolar complex involvement predictive index (NACPI) for indicating nipple sparing mastectomy in breast cancer
Presenter: Hirohito Seki
Session: Poster display - Cocktail
Resources:
Abstract
938 - Multicenter Trial for Safety and Toxicity of Nanoxel®M in Breast Cancer
Presenter: Tae Hyun Kim
Session: Poster display - Cocktail
Resources:
Abstract
1129 - Implication of PET-CT to improve negative predictive value for axillary lymph node metastasis in early breast cancer
Presenter: Oyeon Cho
Session: Poster display - Cocktail
Resources:
Abstract